AIToday
Large Language ModelsAI in HealthcareOpenAI BlogPublished: Sep 11, 2026, 04:00 JST2 min read

De la Fuente lab uses ChatGPT, Codex to hunt new antibiotics

De la Fuente lab uses ChatGPT, Codex to hunt new antibiotics

3 Key Points

  1. What happened

    Bioengineer César de la Fuente's lab uses ChatGPT and Codex alongside its own deep-learning models to search genomes for antimicrobial candidates, cutting the initial search from years to hours.

  2. Why it matters

    The lab turns biology into an information system, reading DNA and peptides as an alphabet to find signals across vast datasets, rather than modifying existing antibiotics—a path de la Fuente says has yielded no new antibiotic class in 50 years.

  3. What to watch

    AI only narrows the candidate list; the test is whether lab validation and years of trials turn any molecule into an approved drug. Watch the projected annual death toll, roughly doubling by 2050.

WHO IT HITSThis lands on drug-discovery researchers and cross-disciplinary lab teams who spend years screening molecules, showing how AI tools can compress that early search. It matters most for teams hunting new antibiotics as resistance grows.

Ask the AI about this article →

Summaries like this, in your inbox every morning.

Context & Analysis

De la Fuente's lab is trying to solve a familiar bottleneck in drug discovery: finding a promising molecule takes years. The lab's answer is to treat biology as an information system. DNA and peptides are, in his words, like an alphabet, and deep-learning models can be trained to read patterns across genome and protein datasets far faster than manual screening. That approach can shrink the earliest search phase from years to hours.

The lab works across biology, chemistry, computer science, and engineering. ChatGPT and Codex help bridge those disciplines: biologists can write code, programmers can work on biological problems, and members can review unfamiliar topics or process large datasets in their native languages. De la Fuente also uses AI as a brainstorming partner, feeding it ideas from many lab members, though he cautions that accuracy must always be double-checked.

A promising candidate, however, is only a starting point. Before any molecule becomes a medicine, it must be confirmed to kill the target microbe, tested for safety and toxicity, assessed for how readily resistance develops, and manufactured reliably, then face regulatory review and clinical trials. The outcome hinges on that slow, grounded work joining the fast AI search—which is exactly why de la Fuente argues AI and laboratory biology must advance together.

FAQ
How much faster is the AI search?
De la Fuente's lab says the approach can reduce the initial search for candidate molecules from years to hours.
Why is this research needed now?
About five million deaths in 2021 were associated with bacterial antimicrobial resistance, a toll projected to roughly double by 2050. De la Fuente also says there has been no new class of antibiotics for 50 years.
Does an AI-found candidate mean a new antibiotic?
No. Scientists must still confirm the molecule kills the target microbe, test its effects on human cells, and run further tests, regulatory review, and clinical trials.

Get the latest Large Language Models news every morning

For example, today's edition would include:

  • DeepSeek V4.1-Flash: 763B model beats V4 Pro on AA Index 40Latent Space · 38m ago
  • Dynatrace acquires Arize AI as observability shifts to actionSiliconANGLE AI · 6h ago
  • Shared base cuts 100 fine-tunes from 1.5 TB to 19.3 GBDaily Dose of Data Science · 6h ago

AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. Q&As are published on this page for other readers too.

Related Articles

Next articleTypewise launches Nova to run customer-service AI agents